The goal of a business integrity agreement is to "create enough security slides that, at least in the future, are very difficult to obtain," says Thomas Beimers, special advisor for health fraud at the law firm Faegre Baker Daniels. This may be the first agreement to put in place enough road slides to achieve this goal, he says. These changes ensure that the company`s programs and activities are well controlled and move towards changing stakeholder expectations. Most importantly, the changes reflect the company`s core values and ensure that its activities and relationships are transparent, based on integrity and respect, and focus on patient well-being. The company`s U.S. business practices now comply with or exceed the U.S. PhRMA code, which governs interactions with healthcare professionals. The company integrity agreement could serve as a roadmap for pharmaceutical compliance programs. It contains the following provisions: communications to health care providers and paying organizations. As a general rule, pharmaceutical companies that are part of an agreement on the integrity of the company must inform physicians in writing of the comparison. This agreement goes even further by requiring GSK to send letters to the government and other payers with whom the company has discount agreements and inform them of the comparison. Colgan adds that in recent years, GSK has also "significantly strengthened the compliance program and staff training." The company now has eight compliance assistants and 79 "integrity champions." This resolution marks the culmination of an in-depth investigation by HHS-OIG special agents, the FDA and the FBI, as well as law partners throughout the federal government.

In the future, GSK will be subject to strict requirements as part of its enterprise integrity agreement with HHS-OIG; This agreement aims to increase accountability and transparency and prevent future fraud and abuse. Effective law enforcement and fraud prevention partnerships are the hallmarks of the Health Care Fraud Prevention and Enforcement Action Team (HEAT), which promotes government cooperation in the fight against fraud. In the publication, Deirdre Connelly, President of GSK, North American Drugs, "Doctors have told us that they want to see fewer distribution professionals, and those who see them need to offer more value in improving patient health. In response, we are changing the way we sell our medicines and vaccines to deliver the value our customers demand in a transparent, integrity and respect for the patient. "We are firmly committed to doing everything in our power to meet and exceed the expectations of those with whom we work and serve. Since I bed CEO, we have a clear priority to anchor a culture that puts patients first, that acts transparently, respects people inside and outside the organization and demonstrates integrity in everything we do. In the future, GSK will be subject to strict requirements as part of its Business Integrity Agreement (CIA) with the Department of Health and Human Services (HHS), the Office of the Inspector General (OIG). This agreement aims to increase accountability and transparency and prevent future fraud and abuse. OIG Inspector General Daniel R. Levinson was also quoted as saying: "Our five-year integrity agreement with GlaxoSmithKline requires individual responsibility on the board of directors and executives....

For example, business leaders may have to let annual bonuses expire if they or their subordinates commit serious misconduct, and salespeople are now paid on the basis of the quality of services and not sales objectives. In recent months, the government has tracked or resolved similar cases in the pharmaceutical industry, including a $2.3 billion comparison against Pfizer and a $1.5 billion comparison against Abbott Laboratories.